BPC-157 (also known as BPC-157) is a performance-enhancing peptide studied for its effects on healing, recovery, tissue repair. Synthetic gastric-juice peptide for tissue repair, gut healing, and anti-inflammatory effects. Strong animal evidence, limited human trials; not FDA-approved.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid pentadecapeptide derived from a protective protein found in human gastric juice. It works by promoting angiogenesis (new blood vessel formation), enhancing growth hormone receptor expression, and reducing inflammatory cytokines. Primarily researched for accelerating tissue repair, wound healing, gut health, and musculoskeletal injury recovery.
Overview
BPC-157 has shown robust regenerative and cytoprotective effects in preclinical animal studies, particularly for tendon, ligament, muscle injuries, and gastrointestinal disorders.
However, human clinical evidence remains extremely limited with only three small pilot studies conducted to date.
It is not FDA-approved for therapeutic use and is classified as a prohibited substance by the World Anti-Doping Agency (WADA).
While generally well-tolerated in animal studies, quality control concerns exist as it remains an unregulated compound.
BPC-157 is considered investigational and requires more comprehensive human clinical trials to establish safety, efficacy, and proper clinical applications.
Mechanism of action
Speeds healing of tendons, ligaments, muscles, and gut. Reduces inflammation and muscle soreness. Minimizes scar tissue formation.
Reported effects
Effects reported in the literature and from preclinical models include:
- Accelerates injured rat Achilles tendon healing by promoting fibroblast outgrowth from tendon explants, enhancing cell survival under oxidative stress, and dose-dependently increasing fibroblast migration via FAK-paxillin pathway activation [3][1] Preclinical
- Promotes angiogenesis, fibroblast activity, and neuromuscular stabilization by activating VEGFR2 through the Akt-eNOS nitric oxide axis and ERK1/2 signaling, particularly in poorly vascularized tissues such as tendons and myotendinous junctions [1] Preclinical
- Acts as a cytoprotectant with reported protective and regenerative activity across multiple organ systems, notably the gastrointestinal tract, in animal and mechanistic studies [2][6][7] Preclinical
- Produces concentration-dependent, endothelium-dependent vasorelaxation in isolated human internal mammary artery rings, predominantly mediated via the endothelial nitric oxide synthase pathway [5] Preclinical
- Intravenous infusion of up to 20 mg in 2 healthy adults produced no measurable adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers and was well-tolerated in an IRB-approved pilot study [4][6] Phase I
- Exhibits a sub-30-minute plasma half-life with linear dose-proportional kinetics and intramuscular bioavailability of 14-51% in preclinical species, with no validated pharmaceutical-grade formulation or completed Phase II trial to date [6] Preclinical
Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal
Dosage and administration
Subcutaneous
- Beginner: 200-250mcg daily, split into 2 doses (100-125mcg each, 12 hours apart)
- Intermediate: 300-400mcg daily, split into 2 doses (150-200mcg each, 12 hours apart)
- Acute injury: 400-500mcg daily for 2-4 weeks, then reduce to maintenance
Oral
- General: 500-1000mcg daily (lower bioavailability, better for gut issues)
Cycle
- 4-8 weeks on, 2-4 weeks off
Weight
- based: 2.5-3.75mcg per kg body weight, taken twice daily
Natty status
BPC-157 is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.[8] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.
Research
The peptide has been the subject of 13 studies and reference works collected on this site. The full bibliography is in § External links below.
Related compounds
Other peptides in this catalogue with overlapping mechanisms or status:
References
- a b Narrative review on regeneration or risk
- ^ Gastric cytoprotection study
- ^ Tendon healing study
- ^ Safety evaluation
- ^ Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
- a b c BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Recent review
- ^ Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation. Recent review
- a b World Anti-Doping Agency. (2026). Prohibited List 2026.
External links
- Wikipedia article
- Systematic review of musculoskeletal healing
- Wound healing mechanisms research
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
- 10mg BPC-157 — commercial
- Bacteriostatic Water Reconstitution Solution 10ml — commercial
This page was last updated on July 17, 2026, at 16:18 (UTC).
Research last reviewed on July 17, 2026.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.